Internet and new drugs: A challenge for public health

May 08, 2012

Barcelona, 8th May 2012. A group of researchers from the IMIM (Hospital del Mar Research Institute) and from the INAD (Hospital del Mar Neuropsychiatry and Addictions Institute) has participated in an international study aiming to give a general overview at a chemical, pharmacological and behavioural level of a recently appeared new chemical compound, according to the Recreational Drugs European Network, as a new abused drug: methoxetamine (MXE).

This new drug, similar to ketamine, is a dissociative drug, meaning it distorts visual and auditory perceptions making one feel separated or "dissociated" from the environment and from oneself, without a loss of consciousness. As the researchers explain "It seems to increase the sense of humour and has strong hallucinogenic properties".

The researchers add that "one of the dangers of these new compounds such as MXE is that most of them are not approved for human consumption and consuming them could be associated to an unknown number of side effects and adverse reactions that have not been described". Information at a toxicological or pharmacological level as well as on users is nearly nonexistent.

In this sense, these new compounds are becoming more and more sophisticated, are usually synthesized in clandestine laboratories, simply by modifying the molecular structure of the substances that are already controlled, with the aim of maintaining a lack of regulation for the largest possible time, and are rapidly spread over the Internet.

In the specific case of MXE, it would seem that its toxicity and side effects would be similar to those of ketamine, a dissociative anaesthetic used in medicine and veterinary that, when used in sub-anaesthetic doses, leads to a range of effects going from a light drunkenness, perceptive stimulation or distortion to the appearance of death-like experiences or body splitting. The main difference when comparing MXE to ketamine, however, is that the duration and intensity of these effects are longer lasting.

In the study, researchers have detected that stores selling this drug over the internet, are advertising it and selling it as a legal alternative to ketamine, since it can be purchased legally without needing a veterinary licence and at a better price. This has meant that it has become extremely popular among consumers and has affected the risk perception associated to consumption, given that many consumers associate legality to safety.

The combination of new synthetic abusive drugs and the speed at which information is spread over the Internet have caused the experts' concern for toxicological, pharmacological or public health issues increase. Experts consider it necessary to have a greater collaboration at an international level to tackle this phenomenon consisting of easily accessible psychoactive drugs over the internet, which is growing rapidly at present.
-end-
This study is part of two projects; the Psychonaut Web Mapping Project and the ReDNet Research Project, funded by the European Commission in the framework of the Public Health Program.

Reference article:

"Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine". Ornella Corazza, Fabrizio Schifano, Pierluigi Simonato, Suzanne Fergus, Sulaf Assi, Jacqueline Stair, John Corkery, Giuseppina Trincas, Paolo Deluca, Zoe Davey, Ursula Blaszko, Zsolt Demetrovics, Jacek Moskalewicz, Magi Farre, Liv Flesland, Manuela Pasinetti, Cinzia Pezzolesi, Agnieszka Pisarska, Harry Shapiro, Holger Siemann, Arvid Skutle, Aurora Enea, Giuditta di Melchiorre, Elias Sferrazza, Marta Torrens, Peer van der Kreeft, Daniela Zummo and Norbert Scherbaum. Hum. Psychopharmacol Clin Exp 2012; 27: 145.

IMIM (Hospital del Mar Medical Research Institute)

Related Ketamine Articles from Brightsurf:

Ketamine, a painkiller used by the army, does not impair tolerance to blood loss
A low dose of ketamine, administered intravenously, does not alter a healthy human's tolerance to blood loss.

New study finds antidepressant drug effective in treating "lazy eye" in adults
In a new study, published in Current Biology, researchers from the University of California, Irvine School of Medicine reveal how subanesthetic ketamine, which is used for pain management and as an antidepressant in humans, is effective in treating adult amblyopia, a brain disorder commonly known as ''lazy eye.''

Depression risk detected by measuring heart rate changes
For the first time doctors have shown that measuring changes in 24-hour heart rate can reliably indicate whether or not someone is depressed.

High doses of ketamine can temporarily switch off the brain, say researchers
Researchers have identified two brain phenomena that may explain some of the side-effects of ketamine.

New study shows how ketamine combats depression
The anaesthetic drug ketamine has been shown, in low doses, to have a rapid effect on difficult-to-treat depression.

JNK protein triggers nerve cells to withdraw their synapses when stressed
New study from Eleanor Coffey's lab at Turku Bioscience Center in Finland identifies that the JNK protein triggers nerve cells to withdraw their synapses when stressed.

Ketamine use is underreported -- likely due to unknown exposure -- among EDM partygoers
Nearly 37% of electronic dance music (EDM) party attendees test positive for ketamine use when samples of their hair are tested -- despite only 14.6% disclosing that they have used the drug in the past year.

Common genetic link between autism and Tourette's impairs brain communication
Scientists have discovered how a genetic alteration that increases the risk of developing Autism and Tourette's impacts on the brain.

Single dose of ketamine plus talk therapy may reduce alcohol use
A single infusion of ketamine plus behavioral therapy helped alcohol-dependent individuals reduce their drinking, a new study finds.

One shot of ketamine could reduce problem drinking
A one-off dose of ketamine could help heavy drinkers reduce their alcohol intake, finds a new UCL experimental study published in Nature Communications.

Read More: Ketamine News and Ketamine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.